Overview · Filed: —
APL_40470/2024
TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
AppealsMain AppealCourt of AppealAppeal RoP220.1—
Parties
Claimants
- Alexion Pharmaceuticals, Inc.(AstraZeneca Group)
Reps: Wolrad Prinz zu Waldeck Und Pyrmont (Freshfields Bruckhaus Deringer); Christopher Stothers (Freshfields Bruckhaus Deringer); Elena Hennecke (Freshfields Bruckhaus Deringer); Gregor König (Szynka Tilmann von Renesse); Claudia Hertzsch (Szynka Tilmann von Renesse)
Respondents
- Samsung Bioepis NL B.V.
Reps: Andrea Ritter (Simmons & Simmons); Peter Meyer (Simmons & Simmons); Scott Parker (Simmons & Simmons); Elsa Glauert (Simmons & Simmons); Fritz Lahrtz (Simmons & Simmons)
Judges
- Klaus GrabinskiPresident of the Court of Appeal
- Peter BlokLegally qualified judge and judge-rapporteur
- Emmanuel GougéLegally qualified judge
- Eric EnderlinTechnically qualified judge
- Anna HedbergTechnically qualified judge
Patents
- EP3167888
CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…
Sector: Organic Chemistry
Outcome
PI denied
Filed: —
First decided: Dec 20, 2024
Language: —
The Court of Appeal dismissed Alexion's appeal against the Hamburg Local Division's refusal to grant provisional measures against Samsung Bioepis regarding patent EP 3167888. The Court addressed the interpretation of patent claims containing linguistic errors and the relevance of prosecution history.